Straight Path Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.52M Buy
54,064
+500
+0.9% +$13.3K 0.41% 27
2025
Q4
$1.33M Sell
53,564
-452
-0.8% -$11.4K 0.36% 28
2025
Q3
$1.38M Sell
54,016
-200
-0.4% -$4.94K 0.37% 33
2025
Q2
$1.31M Buy
54,216
+16,409
+43% +$383K 0.45% 27
2025
Q1
$958K Buy
37,807
+200
+0.5% +$5.23K 0.39% 27
2024
Q4
$998K Sell
37,607
-605
-2% -$16.4K 0.39% 30
2024
Q3
$1.11M Buy
38,212
+1,187
+3% +$34.6K 0.48% 26
2024
Q2
$1.04M Buy
37,025
+6,513
+21% +$179K 0.53% 25
2024
Q1
$847K Buy
+30,512
New +$847K 0.48% 28

Other funds holding PFE

Straight Path Wealth Management's PFE Position: Q1 2026 in Review

Straight Path Wealth Management increased its Pfizer (PFE) stake by 0.93% in Q1 2026, buying an estimated $13.3K and bringing the position to 54,064 shares worth $1.52M. The position accounts for 0.41% of the portfolio, ranked #27.

Straight Path Wealth Management first reported a position in PFE in Q1 2024 and has held it in 9 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Straight Path Wealth Management held 54,064 shares of Pfizer worth $1.52M as of Q1 2026.
  • Straight Path Wealth Management bought 500 Pfizer shares in Q1 2026, an estimated $13.3K.
  • Pfizer made up 0.41% of Straight Path Wealth Management's portfolio in Q1 2026, its #27 holding.
  • Straight Path Wealth Management first reported a position in Pfizer in Q1 2024 and has held it in 9 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Straight Path Wealth Management's 13F filing for Q1 2026, filed 23 Apr 2026.